Elissa Kalver was diagnosed with HER2-positive metastatic breast cancer at 34. Since then, she has founded a nonprofit and ...

Claudine Isaacs, MD: For this patient who's progressed after more than 12 months with an ESR1 mutation and HER2-low disease ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Now, if ever there ...

A guide for patients to understand HER2-positive breast cancer, treatment options by stage and how to talk with your oncologist.

There are three main subtypes and they’re grouped by three genetic markers your doctor will look for on a biopsy specimen: ...

Biomarkers are measurable indicators that can be tested to reveal important details about a cancer. Information about these biomarkers can help guide the best treatment for you, predict your response ...

For patients with high-risk HER2-positive early breast cancer who have undergone neoadjuvant therapy, treatment with Enhertu ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Joining me today ...

Findings from DESTINY-Breast11 showed T-DXd followed by THP demonstrated a statistically significant and clinically meaningful improvement in pCR rate vs ddAC-THP.

An update from Imagion Biosystems Ltd. ( (AU:IBX) ) is now available. Imagion Biosystems has completed the manufacturing of its MagSense® HER2 Breast Cancer Imaging Agent, marking a significant ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- The ...

In an interview with Targeted Oncology, Gerrina Ruiter, MD, PhD, Netherlands Cancer Institute and study investigator, ...